Technology ID
E-337-2003-0

Isolation of Hybridomas Producing Monoclonal Antibodies (MAbs) Inhibitory to Human CYP2J2

Linked ID
TAB-777
Inventors
Darryl Zeldin (NIEHS)
Harry Gelboin (NCI)
Jennifer Bradbury (NIEHS)
Kristopher Krausz (NCI)
Lead Inventors
Darryl Zeldin (NIEHS)
Co-Inventors
Harry Gelboin (NCI)
Jennifer Bradbury (NIEHS)
Kristopher Krausz (NCI)
Development Status
In vitro data available
Applications
Research Materials
ICs
NIEHS
NCI
Commercial Applications
  • These antibodies can be used to identify and quantify inter-individual variation in physiological functions.
  • These antibodies can be used to study pharmacological drug metabolism in various tissues.
The National Institutes of Health announces three specific monoclonal antibodies that strongly inhibit and/or immunoblot the human cytochrome P450 2J2 (CYP2J2).

Cytochrome P450s catalyze the NADPH-dependent oxidation of arachidonic acid to various eicosanoids found in several species. The eicosanoids are biosynthesized in numerous tissues including pancreas, intestine, kidney, heart and lung where they are involved in many different biological activities.

MAb 6-5-20-8 selectively inhibits CYP2J2-mediated arachidonic acid metabolism by more than 80% and also immunoblots the enzyme. MAb 6-2-16-1 also selectively inhibits arachidonic acid metabolism by more than 80% but does not immunoblot the enzyme. MAb 5-3-2-2 is not inhibitory but selectively immunoblots the enzyme. These antibodies can be used to identify and quantify inter-individual variation in physiological functions and to study pharmacological drug metabolism in various tissues.
Competitive Advantages
These antibodies strongly inhibit and/or immunoblot the human cytochrome P450 2J2 (CYP2J2).

Request More Info

Licensing Contact